ANR Anatara Lifesciences Ltd
Healthcare · Biotechnology
· website
$0.01
52wk 0.01 – 0.02
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$3.16M
P/E (trailing)
—
P/E (forward)
0.50
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.69
EV / EBITDA
-1.57
Price / Book
2.50
ROE
-105.2%
Operating margin
-288.8%
Net margin
-209.8%
Total cash
$1.09M
Total debt
$0
Current ratio
7.03
Debt / Equity
—
Free cash flow
$-612,716
Avg volume
433,532
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income—
- Net income—
- Diluted EPS-0.01
- Free cash flow—
- Net debt—